We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Relugolix

News List

Pfizer, Myovant begin dosing in relugolix contraceptive study pharmatimes
April 15, 2021
Pfizer and Myovant have announced that dosing has begun in a Phase III study evaluating the contraceptive efficacy of their relugolix combination tablet.
Relugolix shows potential long-term benefit in women with uterine fibroids pharmatimes
March 26, 2021
Pfizer and Myovant Sciences have announced that relugolix combination therapy could have ‘potential benefit’ for the long-term treatment of women with uterine fibroids.
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids drugs
May 20, 2019
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids.